An update on Prothena

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Neil Woodford 22 November 2017 Est. reading: 7 min read

There is demand for an update on our view of Prothena, following recent coverage and last week’s R&D day. This isn’t a response to any particular note. Research is published on a range of stocks every day, covering a range of different views – we haven’t commented on them in the past, nor do we intend to start now. It is simply an update on where we are today, with a focus on the opportunity for NEOD001 in the rare disease, AL Amyloidosis.


A comprehensive write-up on the background to the investment in Prothena can be found in last year’s company spotlight.

The position in Prothena – and indeed the conviction in the investment case that has contributed to the size of the holding – is the product of a long-standing relationship with the company and its management team, which pre-dates its existence as an independent company (it was spun out of Elan in 2012 at a share price of about $7 and it has been invested in the funds I have managed ever since). In turn, this has allowed me to build a very good understanding of the science that lies behind Prothena’s therapeutic assets and the progress that these assets are making through the clinic.

It is worth remembering that the position size in the funds is also partly the product of the positive share price performance seen from the stock over the last three-to-four years, despite the continued, and increasingly vocal, presence of short positions. I can understand that the publication of negative research can be disconcerting for investors but please bear in mind that the share price today, even after the recent setback, is higher than the average price at which we bought the shares (average book price for WEIF = c. $35, WPCT = c. $40, current share price = c. $46 1).

What has changed?

In last week’s R&D day, Prothena gave a series of confident, evidence-based presentations to update shareholders on its progress. Despite a lot of positive, reassuring information in the presentations across a range of its late-stage and earlier-stage assets, the market appears to have focused on a delay in its Vital Phase III study read-out – a pivotal trial investigating NEOD001 in AL Amyloidosis – as a key negative.

I believe this is the wrong thing to focus on and the wrong conclusion to draw.

There are two ongoing late-stage trials in NEOD001 in AL Amyloidosis (Pronto and Vital). Without wishing to get bogged down in the science, the Pronto trial has been designed to align with feedback from the European Medicines Agency (EMA), with the biomarker ‘NT-proBNP’ as a primary endpoint. The Vital trial, meanwhile, has an event-based primary endpoint. Whilst both are ‘blinded’ studies (in which the data is not disclosed to patients, clinicians or the company until the trial completes), Prothena were able to provide some limited information on their progress, which I have summarised below.


Pronto is a Phase IIb study, which remains on track, due to read out in Q2 2018.

  • Prothena reported the baseline characteristics of patients enrolled, which were nearly identical to the those in the prior Phase I/II study – whilst this does not inform us of any likely outcome, it is encouraging and reaffirms our conviction that the study should read out positively
  • The prior trial (Phase I/II) treated 69 patients in total – the patients enrolled had a range of specific organ dysfunctions (heart, kidney, peripheral neuropathy) and across the board, the data was excellent with organ responses of 53%, 63% and 82% respectively
  • Relating the prior trial to Pronto’s primary endpoint, it is the cardiac patients that are most comparable – there were 36 patients with cardiac involvement and 19 of them (53%) met the primary endpoint of a cardiac response
  • Pronto has been powered to be a success if patients show a 26.5% better response rate than the placebo (the control group in the study) – it was originally intended to be a 100 patient study but due to patient demand, Prothena over-enrolled so the study is now treating 129 patients
  • The gap between the response rate seen in the Phase I/II study and the response rate required to deliver success from Pronto, provides a considerable margin of safety against a placebo response, as does the fact that AL Amyloidosis is a progressive disease in which patient symptoms are worsening
  • Success in the Pronto trial would likely lead to EU approval


Vital is a US Phase III study. Previously expected to read out in H2 2018, Prothena announced at its R&D day last week, that has been pushed out to H2 2019. Having spent some time trying to understand the causes of this delay, I am very encouraged about the progress of this trial.

  • The primary endpoint in this trial is not related to the NT-proBNP biomarker – it is based on the time taken for ‘events’ – in this instance, cardiac hospitalisation or death – to occur
  • The original trial timeline appears to have been guided by the largest (>2,000 patients) collection of AL Amyloidosis patient data available
  • The announcement of a one-year delay to the primary endpoint means that events are not occurring as fast as Prothena had expected
  • This can only be for two reasons
    1. The standard of care has improved (or is better than the dataset had suggested)
    2. NEOD001 is working
  • On standard of care, we know that AL Amyloidosis patients are generally living longer than they used to but that should have been captured by the dataset on which the original trial timelines appear to have been based – we do not believe that anything meaningful has happened to change the standard of care since the trial commenced
  • The R&D day also contained new information about patient baseline characteristics in the Vital trial, which showed that it includes a greater proportion of more severely affected patients, in which the disease has progressed further
  • One should expect events in these patients to occur faster – but the trial read out, however, has been delayed by a year because events appear to be occurring slower than anticipated
  • Overall, therefore, in my view, the delay of the Vital trial read-out is a very promising sign that NEOD001 is working

Prothena: the journey so far

Source: Bloomberg, Woodford

The company was established (spun out from Elan)DECEMBER 2012Prothena releases encouraging trial data from its phase I/II study for NEOD001 JULY 2016Prothena hosts R&D day, highlighting breadth of novel pipelineNOVEMBER 2017 Prothena announces initiation of Pronto, a phase llb trial for NEOD001OCTOBER 2015Prothena initiates Vital, a phase III trial for NEOD001DECEMBER 2014Woodford Patient Capital Trust’s first investment in ProthenaAPRIL 2015 Woodford Equity Income Fund’s first investment in ProthenaJUNE 2014Prothena reports results from phase Ib study for PRX002, its potential disease-modifying treatment for Parkinson’sNOVEMBER 2016 Prothena initiates its phase II Pasadena study for PRX002, triggering $30m milestone payment from Roche JULY 2017$7$46

Prothena: the journey so far

Source: Bloomberg, Woodford


I rate the Prothena team very highly – it’s expertise in misfolded proteins and central nervous system disease biology is, in my view, second to none. It is extremely rare to see a biotech so swiftly and so successfully progress from the pre-clinical to the pivotal trial stage.

The business is fully-funded to deliver on the significant value inflection points that lie ahead, with NEOD001 poised to do that in the near future. No external factors can affect that now.

There is no such thing as certainty in the world of investment and I have never and would never claim that there was. However, my conviction in the long-term Prothena investment case is as strong as it ever has been.

What are the risks?

  • The value of investments and any income from them may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The ongoing charges figure is charged to capital, so the income of the funds may be higher but capital growth may be restricted or capital may be eroded
  • The funds may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits – some of these security types could increase the funds’ volatility and increase the level of indirect charges to which the funds are exposed
  • The funds and trust may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the sterling value of these investments and the income from them, to fluctuate
  • The LF Woodford Income Focus Fund will be invested in a concentrated portfolio of securities – the fund is not restricted by reference to any geographical region, sector or market capitalisation
  • The LF Woodford Equity Income Fund and the Woodford Patient Capital Trust may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value
  • The price of shares in the Woodford Patient Capital Trust is determined by market supply and demand, and this may be different to the net asset value of the trust. This means the price may be volatile in response to changes in demand
  • Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses
  • Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy – it can take years for young businesses to fulfil their potential, this investment requires patience

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund – or Key Information Document (KID) for the trust – and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

The Woodford Patient Capital Trust currently intends to conduct its affairs so that its securities can be recommended by IFAs to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at


Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address: 27 Old Gloucester Street, London, WC1N 3AX.

© 2019 Woodford Investment Management Ltd.
All rights reserved.

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.

Privacy Preference Center

Experience Tracking

Lets our analytics service track you across our different websites and enables data sharing among our different marketing tools.

AMCV_[Tracker ID]@AdobeOrg (Adobe), [Tracker ID]@AdobeOrg (Adobe)
Adobe Analytics (helps us provide you with more relevant experiences and content based on your likely interests). Cookies: demdex, dextp, dpm, DST, DSTJS
Twitter personalisation (by better understanding how devices are related, Twitter can use information from one device to help personalize the Twitter experience on another device). Cookies: personalization_id
Heap Analytics (provides metrics on user behaviour and actions throughout the site). Cookies: _gid, _hp2_id.[Tracker ID],_hp2_props.[Tracker ID], _ga, _mkto_trk, optimizelyBuckets, optimizelyEndUserId, optimizelySegments, raygun4js-userid, _attribution_referrer, _csrf
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: _tmae ,ev_sync_dd,ev_sync_yh,everest_g_v2,gglck

Traffic Metrics

Allows Woodford to aggregate information on website usage and popular content

_ga, _gid
Google Analytics (tracks and reports website traffic and user behaviour): Cookie: CONSENT
New Relic (application and server performance monitoring – allows us to spot problems with our website code and improve them to keep things running smoothly). Cookie: JSESSIONID
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: __qca,__smToken, _ga, _mkto_trk, _rtbmedia

Search History

Populates the 'recent searches' section of the website navigation.


Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?